000 | 01965 a2200541 4500 | ||
---|---|---|---|
005 | 20250513154626.0 | ||
264 | 0 | _c19990218 | |
008 | 199902s 0 0 eng d | ||
022 | _a1078-0432 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aSchwartz, G K | |
245 | 0 | 0 |
_aA pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. _h[electronic resource] |
260 |
_bClinical cancer research : an official journal of the American Association for Cancer Research _cApr 1997 |
||
300 |
_a537-43 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
650 | 0 | 4 | _aDose-Response Relationship, Drug |
650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
650 | 0 | 4 | _aDrug Administration Schedule |
650 | 0 | 4 |
_aEnzyme Inhibitors _xadministration & dosage |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aInfusions, Intravenous |
650 | 0 | 4 |
_aLeukopenia _xchemically induced |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMetabolic Clearance Rate |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aNeoplasms _xblood |
650 | 0 | 4 | _aPilot Projects |
650 | 0 | 4 |
_aProtein Kinase C _xantagonists & inhibitors |
650 | 0 | 4 | _aRegression Analysis |
650 | 0 | 4 |
_aSphingosine _xadministration & dosage |
650 | 0 | 4 |
_aThrombocytopenia _xchemically induced |
700 | 1 | _aWard, D | |
700 | 1 | _aSaltz, L | |
700 | 1 | _aCasper, E S | |
700 | 1 | _aSpiess, T | |
700 | 1 | _aMullen, E | |
700 | 1 | _aWoodworth, J | |
700 | 1 | _aVenuti, R | |
700 | 1 | _aZervos, P | |
700 | 1 | _aStorniolo, A M | |
700 | 1 | _aKelsen, D P | |
773 | 0 |
_tClinical cancer research : an official journal of the American Association for Cancer Research _gvol. 3 _gno. 4 _gp. 537-43 |
|
999 |
_c9779934 _d9779934 |